Press Release

Jan, 04 2024

Breakthroughs in Respiratory Health: China's FeNO Testing Market Surges, Paving the Way for Better Care

The China FeNO (fractional exhaled nitric oxide) testing market is experiencing unprecedented growth driven by the escalating prevalence of respiratory disorders. This non-invasive diagnostic method, measuring airway inflammation, has gained prominence in China's healthcare landscape. With rising pollution levels and increasing asthma and related respiratory conditions, the demand for FeNO testing has surged. As a result, the market is witnessing substantial expansion, transforming the way respiratory ailments are diagnosed and managed across the country.

Access full Report @

Data Bridge Market Research analyses that the China FeNO Testing Market is expected to grow at a CAGR of 13.9% during the forecast period of 2023 to 2030 and is expected to reach USD 66,564.09 million by 2030 from USD 23,499.05 million in 2022. Investment in research and development from the public and private sectors drives innovation in FeNO testing technologies. This funding supports creating more accurate, user-friendly, and cost-effective methods, enhancing the diagnostic capabilities of FeNO testing. These advancements contribute to better patient care and the overall growth of the FeNO testing market in China.

Key Findings of the Study

China Feno Testing Market

Advancements in FeNO testing technology are expected to drive the market's growth rate

Ongoing technological progress in FeNO testing is revolutionizing respiratory diagnostics. Innovations significantly enhance accuracy and user-friendliness, making it increasingly appealing to healthcare providers. These advancements ensure precise measurements and streamlined procedures, enabling more efficient diagnosis and personalized treatment plans. As a result, FeNO testing has become a cornerstone in diagnosing and managing respiratory disorders, transforming healthcare practices.

Report Scope and Market Segmentation

Report Metric


Forecast Period

2023 to 2030

Base Year


Historic Years

2021(Customizable to 2015-2020)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Type (Nitric Oxide Handheld Monitor, Nitric Oxide Standalone Monitor and Others), Indication (Eosinophilic Airway Inflammation, Atopic Asthma, Chronic Respiratory Symptoms, COPD with Mixed Inflammatory Phenotype, Eosinophilic Bronchitis, Pulmonary Arterial Hypertension, Corticosteroid Responsiveness, Cystic Fibrosis, Others), End User (Hospitals, Diagnostic Centers, Clinics, Ambulatory Surgical Centers, Homecare Setting, Others), Distribution Channel (Direct Tender, Retail Sales, Online Sales).

Market Players Covered

Bedfont Scientific Ltd. (U.K.), Spirosure, Inc (U.S.), Medisoft Limited (Belgium), Bosch Healthcare Solutions GmbH (A Subsidiary of Robert Bosch GmbH) (Germany), Sunvou (China), RuiBreath (China), Circassia (U.K.), ECO MEDICS AG (Switzerland).

Data Points Covered in the Report

In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Segment Analysis:

The China FeNO testing market is segmented on the basis of type, indication, end user, and distribution channel.

  • On the basis of type, the China FeNO testing market is segmented into nitric oxide handheld monitor, nitric oxide standalone monitor, and others
  • On the basis of indication, the China FeNO testing market is segmented into eosinophilic airway inflammation, atopic asthma, chronic respiratory symptoms, COPD with mixed inflammatory phenotype, eosinophilic bronchitis, pulmonary arterial hypertension, corticosteroid responsiveness, cystic fibrosis, others
  • On the basis of end user, the China FeNO testing market is segmented into hospitals, diagnostic centers, clinics, ambulatory surgical centers, homecare setting, and others
  • On the basis of distribution channel, the China FeNO testing market is segmented into direct tender, retail sales, and online sales

Major Players

Data Bridge Market Research recognizes the following companies as the major China FeNO testing market players in China FeNO testing market are Bedfont Scientific Ltd. (U.K.), Spirosure, Inc (U.S.), Medisoft Limited (Belgium), Bosch Healthcare Solutions GmbH (A Subsidiary of Robert Bosch GmbH) (Germany), Sunvou (China), RuiBreath (China), Circassia (U.K.), ECO MEDICS AG (Switzerland).

China FeNO Testing Market

Market Developments

  • In March 2023, a groundbreaking collaboration unfolded in China's FeNO Testing Market as Shanghai Dongfang Hospital achieved a significant milestone. They successfully introduced the nation's inaugural treatment process for refractory asthma and conducted pre-market clinical trials in eight hospitals nationwide. This collaborative effort is pivotal in advancing respiratory care and diagnostics within the Chinese healthcare landscape
  • In 2021, Sinocare, a prominent Chinese healthcare company, announced its acquisition of Guangzhou Weikang Medical Devices Co. This strategic move is set to integrate Weikang's expertise in FeNO testing with Sinocare's expansive healthcare solutions, reinforcing their position in the China FeNO Testing Market. The collaboration is expected to enhance diagnostic accuracy and patient care, fostering market growth and innovation
  • In 2021, Beijing Medcaptain Medical Technology Co. announced its strategic partnership with Shenzhen Mindray Bio-Medical Electronics Co. Ltd. This collaboration aims to integrate Mindray's advanced medical equipment with Medcaptain's expertise in FeNO testing solutions. The partnership is expected to enhance the accuracy and efficiency of FeNO testing in China, further solidifying the market's position and improving patient care
  • In November 2019, PulmOne USA Inc. established a partnership with Circassia Pharmaceuticals, a global company with a presence in China and the U.S. This collaboration aimed to provide the NIOX VERO fractional exhaled nitric oxide (FeNO) measurement system, in conjunction with PulmOne's MiniBox+. This joint effort leveraged the expertise of both companies to enhance respiratory diagnostics and healthcare solutions

 For more detailed information about the China FeNO testing market report, click here –

Client Testimonials